

Table SI. Patient characteristics (n=208).

Variable	Value
Age, years	72 (68-78)
Sex	
Female	64 (30.8)
Male	144 (69.2)
Grade	
Low	29 (13.9)
High	179 (86.1)
pT stage	
pTa	47 (22.6)
pTis	2 (1.0)
pT1	37 (17.8)
pT2	24 (11.5)
pT3	83 (39.9)
pT4	15 (7.2)
pN stage	
pNx	4 (1.9)
pN0	167 (80.3)
pN1	17 (8.2)
pN2	20 (9.6)
LVI	
Absent	90 (43.3)
Present	118 (56.7)
Surgical margin	
Absent	195 (93.8)
Present	13 (6.3)
Divergent differentiation/subtype	
Absent	186 (89.4)
Present	22 (10.6)
Neoadjuvant chemotherapy	
No	196 (94.2)
Yes	12 (5.8)
Adjuvant chemotherapy	
No	164 (78.9)
Yes	44 (21.2)
PD-L1	
Low	143 (69.4)

High	63 (30.6)
FGFR3	
Low	19 (9.2)
High	187 (90.8)
Median follow-up, months	72.2 (46.4-96.2)

Data are presented as n (%) or median (interquartile range). LVI, lymphovascular invasion; PD-L1, programmed death-ligand 1; FGFR3, fibroblast growth factor receptor 3.

Table SII. Association of the expression status of various proteins in the cohort.

A, Association between CD155 and FGFR3

CD155	FGFR3	
	Low	High
Low	1 (0.48)	29 (13.9)
High	18 (8.7)	158 (76.0)

B, Association between CD155 and PD-L1

CD155	PD-L1	
	Low	High
Low	26 (12.5)	4 (1.9)
High	117 (56.3)	59 (28.4)

C, Association between FGFR3 and PD-L1

FGFR3	PD-L1	
	Low	Low
Low	9 (4.3)	10 (4.8)
High	134 (64.4)	53 (25.5)

Values are expressed as n (%). PD-L1, programmed death-ligand 1; FGFR3, fibroblast growth factor receptor 3.